GALT

Galectin Therapeutics Inc

3.19

Oct 26 • 3:59 PM ET 0.00 (0.00%)

3.19

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: IVA SGMT ALT MDGL GYRE VKTX MIRM CORT LPCN NVO

| Held by: VTI IWM VXF VTWO IWO IWN IWC VTWG MEDX RSSL

Scroll to Statements

Index	RUT
Market Cap	321.71M
Enterprise Value	448.40M
Income	-28.03M
Sales	0.00M
Book/sh	-2.10
Cash/sh	0.13
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	9
IPO	Sep 04, 2002

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	24.24
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.10
Current Ratio	0.10
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-0.43
EPS next Y	-0.23
EPS next Q	-0.05
EPS this Y	37.50%
EPS next Y	23.33%
EPS next 5Y	-
EPS past 3/5Y	9.53% -3.21%
Sales past 3/5Y	- -
EPS Y/Y TTM	33.25%
Sales Y/Y TTM	-
EPS Q/Q	-16.57%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-55.56% -

Insider Own	52.71%
Insider Trans	-0.20%
Inst Own	15.53%
Inst Trans	7.08%
ROA	-183.01%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-12.27%
SMA50	-16.58%
SMA200	-0.36%
Trades

Shs Outstand	66.31M
Shs Float	47.69M
Short Float	19.31%
Short Ratio	30.38
Short Interest	9.21M
52W High	7.13 -55.26%
52W Low	2.03 57.53%
Volatility	6.88% 6.30%
ATR (14)	0.23
RSI (14)	32.37
Beta	0.53
Rel Volume	0.54
Avg Volume	303.09K
Volume	164,397

Perf Week	-8.73%
Perf Month	-18.21%
Perf Quarter	-5.90%
Perf Half Y	34.60%
Perf YTD	-23.32%
Perf Year	-39.01%
Perf 3Y	53.37%
Perf 5Y	-2.15%
Perf 10Y	308.97%
Recom	1.00
Target Price	11.00
Prev Close	3.19
Price	3.19
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-25	Resumed	H.C. Wainwright	Buy	$6
Aug-13-20	Reiterated	H.C. Wainwright	Buy	$9 → $12
Feb-13-19	Initiated	B. Riley FBR	Buy	$11
Dec-07-17	Reiterated	H.C. Wainwright	Buy	$6 → $10
Nov-28-17	Reiterated	H.C. Wainwright	Buy	$3.50 → $6
Oct-19-17	Initiated	ROTH Capital	Buy
Mar-30-17	Upgrade	H.C. Wainwright	Neutral → Buy	$3.50
Oct-03-16	Downgrade	FBR & Co.	Outperform → Mkt Perform	$12 → $2
Sep-29-16	Downgrade	H.C. Wainwright	Buy → Neutral	$1.50
Sep-28-16	Downgrade	ROTH Capital	Buy → Sell
Mar-28-16	Resumed	H.C. Wainwright	Buy	$8
Sep-21-15	Initiated	H.C. Wainwright	Buy	$7
Aug-01-14	Downgrade	Aegis Capital	Buy → Hold
Jul-30-14	Reiterated	MLV & Co	Buy	$27 → $16
Jul-29-14	Reiterated	MLV & Co	Buy	$27 → $15
Apr-02-14	Reiterated	MLV & Co	Buy	$20 → $27
Feb-10-14	Reiterated	Aegis Capital	Buy	$16 → $32
Jan-09-14	Reiterated	Aegis Capital	Buy	$10 → $16
Dec-03-13	Initiated	MLV & Co	Buy	$20
Aug-19-13	Reiterated	Aegis Capital	Buy	$7 → $10

Show Previous Ratings

Oct-06-26 08:00AM	Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 (GlobeNewswire)
Sep-10-26 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-14-26 08:00AM	Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update (GlobeNewswire)
Aug-04-26 08:00AM	Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet (GlobeNewswire)
Jun-23-26 01:47PM	GALT Stock Surges 22% On Track For Best Day In Over A Year After FDA Clears Path For Late-Stage Belapectin Trial (Stocktwits) +11.43%
08:00AM	Loading…
08:00AM	Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension (GlobeNewswire)
May-27-26 08:00AM	Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis (GlobeNewswire)
May-15-26 08:00AM	Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update (GlobeNewswire) -7.66%
May-11-26 08:00AM	Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology (GlobeNewswire) +5.24%
Mar-31-26 08:00AM	Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.56%
Mar-17-26 08:00AM	Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. (GlobeNewswire)
Feb-26-26 04:05PM	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET (GlobeNewswire) -5.10%
Dec-19-25 08:00AM	Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 (GlobeNewswire) -28.90%
Nov-14-25 08:00AM	Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-10-25 08:00AM	Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Oct-20-25 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference (GlobeNewswire)
Oct-07-25 08:00AM	Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 (GlobeNewswire) +7.43%
Sep-23-25 07:21PM	Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials (Insider Monkey)
Sep-12-25 12:00PM	Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know (Zacks) -9.60%
Sep-02-25 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update (GlobeNewswire)
Jul-09-25 08:00AM	Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 (GlobeNewswire) +7.66%
Jun-18-25 11:19AM	Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going (PR Newswire) +37.66%
Jun-10-25 08:56AM	Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension (GlobeNewswire)
May-15-25 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update (GlobeNewswire)
May-12-25 08:00AM	Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress (GlobeNewswire)
Apr-15-25 08:00AM	Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress (GlobeNewswire)
Apr-07-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-31-25 08:00AM	Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update (GlobeNewswire) -19.74%
Feb-18-25 08:00AM	Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial (GlobeNewswire) +8.51%
08:00AM	Loading…
Jan-10-25 08:00AM	Galectin Therapeutics to Present at the 2025 MASH-TAG Conference (GlobeNewswire)
Dec-20-24 08:00AM	Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH (GlobeNewswire) -48.00%
Dec-09-24 09:35AM	Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks (Zacks) -6.85%
Nov-18-24 08:00AM	Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting (GlobeNewswire)
Nov-14-24 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update (GlobeNewswire) -5.17%
Oct-15-24 08:00AM	Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting (GlobeNewswire)
Sep-30-24 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference (GlobeNewswire)
Sep-03-24 08:30AM	Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -7.24%
Aug-13-24 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update (GlobeNewswire) +6.64%
Aug-01-24 08:00AM	Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer (GlobeNewswire) -10.60%
Jun-04-24 08:00AM	Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress (GlobeNewswire)
May-15-24 12:53PM	GALT Stock Earnings: Galectin Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +7.75%
08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update (GlobeNewswire)
May-13-24 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Apr-09-24 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis (GlobeNewswire) +5.35%
Apr-05-24 08:52AM	GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023 (InvestorPlace) +24.33%
Mar-29-24 09:11AM	Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments (GuruFocus.com)
08:00AM	Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-12-24 08:00AM	Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development (GlobeNewswire)
Nov-13-23 11:11AM	Galectin Therapeutics Inc (GALT) Reports Increased Net Loss in Q3 2023 (GuruFocus.com) -7.14%
08:45AM	UPDATE Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update (GlobeNewswire)
08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update (GlobeNewswire)
Nov-03-23 08:00AM	Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2023, Hosted by the AASLD (GlobeNewswire)
Oct-23-23 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023 (GlobeNewswire)
Oct-12-23 08:00AM	Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of Directors (GlobeNewswire)
Oct-03-23 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Fourth Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Portal Hypertension Caused by Non-Alcoholic SteatoHepatitis Liver Cirrhosis (GlobeNewswire)
Sep-26-23 08:00AM	Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023 (GlobeNewswire)
Sep-13-23 05:22PM	Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 (GlobeNewswire) +6.70%
Sep-11-23 09:55AM	Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden Cross (Zacks)
08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023 (GlobeNewswire)
Sep-07-23 12:00PM	Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023 (GlobeNewswire) +7.32%
Aug-17-23 12:00PM	What Makes Galectin Therapeutics Inc. (GALT) a New Buy Stock (Zacks) +10.19%
Aug-14-23 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update (GlobeNewswire)
May-18-23 04:37PM	7 Short-Interest Stocks to Target for Explosive Gains (InvestorPlace) +6.38%
May-15-23 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update (GlobeNewswire)
Apr-27-23 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023 (GlobeNewswire)
Apr-18-23 08:00AM	Galectin Therapeutics Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver Diseases (GlobeNewswire)
Mar-30-23 08:00AM	Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update (GlobeNewswire) +5.34%
Mar-16-23 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire)
Mar-02-23 08:00AM	Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) +8.29%
Jan-24-23 08:00AM	Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal (GlobeNewswire)
Jan-05-23 08:00AM	Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) -5.04%
Dec-13-22 09:55AM	Bears are Losing Control Over Galectin Therapeutics Inc. (GALT), Here's Why It's a 'Buy' Now (Zacks)
Nov-29-22 08:00AM	Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders (GlobeNewswire)
Nov-28-22 08:00AM	Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit (GlobeNewswire)
Nov-14-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update (GlobeNewswire) +5.56%
Nov-01-22 08:00AM	Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting 2022, Hosted by the AASLD (GlobeNewswire)
Oct-14-22 08:00AM	Galectin Therapeutics to Present in Upcoming Conferences (GlobeNewswire) +5.19%
Oct-12-22 08:00AM	Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer (GlobeNewswire)
Oct-06-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire)
Sep-08-22 08:00AM	Galectin Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference September 13, 2022 (GlobeNewswire) +5.65%
Aug-15-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update (GlobeNewswire) +5.31%
Jul-26-22 08:00AM	Galectin Therapeutics Announces $60 Million Credit Line from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through 2024 (GlobeNewswire)
Jun-21-22 08:00AM	Galectin Therapeutics Announces 2 Liver Cirrhosis Scientific Presentations at the EASL International Liver Congress 2022 (GlobeNewswire)
May-23-22 08:00AM	Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress (GlobeNewswire)
May-16-22 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) -7.35%
May-11-22 11:20AM	Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y (Zacks) -6.47%
May-03-22 08:30AM	Nano Dimensions Preliminary Q1/2022 Revenues: Approximately $10.5 Million (GlobeNewswire)
Apr-15-22 07:20AM	Is Galectin Therapeutics Inc. (NASDAQ:GALT) Popular Amongst Insiders? (Simply Wall St.)
Apr-14-22 08:00AM	Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis (GlobeNewswire) +10.13%
Mar-31-22 08:00AM	Galectin Therapeutics Reports 2021 Financial Results and Provides Business Update (GlobeNewswire) -5.85%
Jan-06-22 08:00AM	Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference (GlobeNewswire)
Dec-21-21 08:00AM	Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein (GlobeNewswire)
Dec-13-21 08:00AM	Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting (GlobeNewswire)
Nov-15-21 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2021, and Provides Business Update (GlobeNewswire)
Nov-05-21 04:24PM	UPDATE Galectin Therapeutics to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD (GlobeNewswire)
Oct-27-21 08:00AM	Galectin Pharmaceuticals to Present Six Scientific Abstracts at The Liver Meeting 2021, Hosted by the AASLD (GlobeNewswire)
Oct-05-21 03:39PM	UPDATE: Galectin Therapeutics to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021 (GlobeNewswire)
01:55PM	Galectin Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference (GlobeNewswire)
Sep-21-21 08:00AM	Galectin Therapeutics Announces $20 Million Convertible Debt Financing from Its Chairman, Richard E. Uihlein (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Uihlein Richard E	Director	Jul 31 '26	Option Exercise	3.08	34,376,167	105,806,980	44,713,843	Aug 04 07:52 AM
Jamil Khurram	Chief Medical Officer	Jul 14 '26	Option Exercise	3.04	16,250	49,400	16,250	Jul 16 05:39 PM
Jamil Khurram	Chief Medical Officer	Jul 14 '26	Sale	5.13	16,250	83,284	0	Jul 16 05:39 PM
Shlevin Harold H.	Director	Jun 29 '26	Option Exercise	1.23	22,268	27,390	28,768	Jun 30 07:24 PM
Shlevin Harold H.	Director	Jun 26 '26	Option Exercise	1.23	7,732	9,510	14,232	Jun 30 07:24 PM
Shlevin Harold H.	Director	Jun 29 '26	Sale	5.04	22,268	112,231	6,500	Jun 30 07:24 PM
Shlevin Harold H.	Director	Jun 26 '26	Sale	5.00	7,732	38,660	6,500	Jun 30 07:24 PM
Jamil Khurram	Chief Medical Officer	Jun 29 '26	Option Exercise	2.50	47,467	118,668	47,467	Jun 30 07:23 PM
Jamil Khurram	Chief Medical Officer	Jun 26 '26	Option Exercise	2.37	4,570	10,814	2,533	Jun 30 07:23 PM
Jamil Khurram	Chief Medical Officer	Jun 29 '26	Sale	5.04	47,467	239,234	0	Jun 30 07:23 PM
Jamil Khurram	Chief Medical Officer	Jun 26 '26	Sale	5.00	4,570	22,850	0	Jun 30 07:23 PM
Harold Shlevin	Director	Jun 29 '26	Proposed Sale	5.04	22,268	112,212		Jun 29 04:09 PM
Jamil Khurram	Officer	Jun 26 '26	Proposed Sale	5.00	68,287	341,435		Jun 26 06:09 PM
HAROLD SHLEVIN	DIRECTOR	Jun 26 '26	Proposed Sale	5.00	7,732	38,680		Jun 26 04:15 PM
Jamil Khurram	Chief Medical Officer	Jun 23 '26	Option Exercise	1.23	7,557	9,295	7,557	Jun 25 04:06 PM
Jamil Khurram	Chief Medical Officer	Jun 23 '26	Sale	3.14	7,557	23,729	0	Jun 25 04:06 PM
Jamil Khurram	Officer	Jun 23 '26	Proposed Sale	3.14	8,125	25,500		Jun 23 04:15 PM
Jamil Khurram	Chief Medical Officer	May 26 '26	Option Exercise	1.23	568	699	568	May 28 09:13 AM
Jamil Khurram	Chief Medical Officer	May 26 '26	Sale	3.10	568	1,761	0	May 28 09:13 AM
ELDRED KARY	Director	Feb 06 '26	Buy	2.70	300	810	65,682	Feb 09 04:25 PM
LEWIS JOEL	President and CEO	Jan 02 '26	Option Exercise	0.00	84,000	0	916,592	Jan 06 04:54 PM
LEWIS JOEL	President and CEO	Jan 06 '26	Sale	3.58	37,698	134,853	832,592	Jan 06 04:54 PM
LEWIS JOEL	President and CEO	Jan 05 '26	Sale	3.91	27,731	108,342	870,290	Jan 06 04:54 PM
LEWIS JOEL	President and CEO	Jan 02 '26	Sale	4.20	18,571	77,939	898,021	Jan 06 04:54 PM
CALLICUTT JACK W	Chief Financial Officer	Jan 02 '26	Option Exercise	0.00	60,000	0	67,614	Jan 06 04:54 PM
CALLICUTT JACK W	Chief Financial Officer	Jan 05 '26	Sale	3.90	25,732	100,298	27,968	Jan 06 04:54 PM
CALLICUTT JACK W	Chief Financial Officer	Jan 06 '26	Sale	3.67	20,354	74,695	7,614	Jan 06 04:54 PM
CALLICUTT JACK W	Chief Financial Officer	Jan 02 '26	Sale	4.20	13,914	58,394	53,700	Jan 06 04:54 PM
Jamil Khurram	Chief Medical Officer	Jan 02 '26	Option Exercise	0.00	60,000	0	60,000	Jan 06 04:53 PM
Jamil Khurram	Chief Medical Officer	Jan 05 '26	Sale	3.90	25,499	99,408	21,446	Jan 06 04:53 PM
Jamil Khurram	Chief Medical Officer	Jan 06 '26	Sale	3.65	21,446	78,205	0	Jan 06 04:53 PM
Jamil Khurram	Chief Medical Officer	Jan 02 '26	Sale	4.20	13,055	54,789	46,945	Jan 06 04:53 PM
Shlevin Harold H.	Director	Jan 02 '26	Proposed Sale	4.16	441,500	1,836,640		Jan 06 11:10 AM
Jamil Khurram	Chief Medical Officer	Dec 31 '25	Option Exercise	1.23	8,125	9,994	8,125	Jan 05 04:07 PM
Jamil Khurram	Chief Medical Officer	Dec 31 '25	Sale	4.07	8,125	33,089	0	Jan 05 04:07 PM
LEWIS JOEL	Officer	Jan 02 '26	Proposed Sale	4.20	84,000	352,800		Jan 02 04:58 PM
Jamil Khurram	Officer	Jan 02 '26	Proposed Sale	4.20	60,000	252,000		Jan 02 04:57 PM
CALLICUTT JACK W	Officer	Jan 02 '26	Proposed Sale	4.20	141,206	593,065		Jan 02 04:56 PM
Jamil Khurram	Officer	Dec 31 '25	Proposed Sale	4.10	8,125	33,313		Dec 31 04:08 PM
ELDRED KARY	Director	Dec 23 '25	Buy	3.73	700	2,611	65,382	Dec 23 01:17 PM
FREEMAN KEVIN D	Director	Dec 23 '25	Buy	3.55	5,500	19,514	55,269	Dec 23 11:29 AM
ELDRED KARY	Director	Dec 23 '25	Buy	3.73	700	2,611	65,382	Dec 23 11:28 AM
LEWIS JOEL	President and CEO	Dec 17 '25	Option Exercise	2.86	7,829	22,391	840,421	Dec 19 04:08 PM
LEWIS JOEL	President and CEO	Dec 17 '25	Sale	7.06	7,829	55,241	832,592	Dec 19 04:08 PM
Jamil Khurram	Chief Medical Officer	Dec 17 '25	Option Exercise	2.37	14,963	35,469	8,500	Dec 19 04:06 PM
Jamil Khurram	Chief Medical Officer	Dec 17 '25	Sale	7.04	19,442	136,872	0	Dec 19 04:06 PM
Shlevin Harold H.	Director	Dec 17 '25	Option Exercise	1.98	20,000	39,600	31,206	Dec 19 04:05 PM
Shlevin Harold H.	Director	Dec 17 '25	Sale	7.04	24,499	172,424	6,500	Dec 19 04:05 PM
10X Fund, L.P.	10% Owner	Dec 16 '25	Sale	6.66	30,681	204,335	5,614,457	Dec 18 10:34 AM
HAROLD SHLEVIN	DIRECTOR	Dec 17 '25	Proposed Sale	6.97	24,706	172,223		Dec 17 04:44 PM
Jamil Khurram	Officer	Dec 17 '25	Proposed Sale	7.04	21,479	151,212		Dec 17 04:33 PM
LEWIS JOEL	Officer	Dec 17 '25	Proposed Sale	7.06	40,000	282,244		Dec 17 04:29 PM
Shlevin Harold H.	Director	Dec 12 '25	Option Exercise	4.16	19,793	82,339	30,999	Dec 16 04:22 PM
Shlevin Harold H.	Director	Dec 15 '25	Option Exercise	4.16	8,417	35,015	19,623	Dec 16 04:22 PM
Shlevin Harold H.	Director	Dec 12 '25	Sale	6.27	19,793	124,181	11,206	Dec 16 04:22 PM
Shlevin Harold H.	Director	Dec 15 '25	Sale	6.30	8,417	53,027	11,206	Dec 16 04:22 PM
HAROLD SHLEVIN	DIRECTOR	Dec 15 '25	Proposed Sale	6.24	8,417	52,542		Dec 15 04:32 PM
HAROLD SHLEVIN	DIRECTOR	Dec 12 '25	Proposed Sale	6.21	19,793	122,993		Dec 12 05:27 PM
Shlevin Harold H.	Director	Dec 08 '25	Option Exercise	2.07	155,000	320,950	46,206	Dec 10 08:15 AM
Shlevin Harold H.	Director	Dec 09 '25	Option Exercise	4.16	16,790	69,846	27,996	Dec 10 08:15 AM
Shlevin Harold H.	Director	Dec 08 '25	Sale	5.98	159,000	950,105	11,206	Dec 10 08:15 AM
Shlevin Harold H.	Director	Dec 09 '25	Sale	6.27	16,790	105,206	11,206	Dec 10 08:15 AM
HAROLD SHLEVIN	DIRECTOR	Dec 09 '25	Proposed Sale	6.21	16,790	104,198		Dec 09 04:36 PM
HAROLD SHLEVIN	DIRECTOR	Dec 08 '25	Proposed Sale	6.02	159,000	957,180		Dec 08 07:40 PM
10X Fund, L.P.	10% Owner	Dec 03 '25	Sale	5.73	120,000	687,600	5,682,207	Dec 04 04:57 PM
10X Fund, L.P.	10% Owner	Dec 02 '25	Sale	5.47	30,000	164,100	5,802,207	Dec 04 04:57 PM
LEWIS JOEL	President and CEO	Nov 17 '25	Option Exercise	2.39	15,680	37,475	848,272	Nov 19 04:01 PM
LEWIS JOEL	President and CEO	Nov 18 '25	Option Exercise	2.39	6,783	16,211	839,375	Nov 19 04:01 PM
LEWIS JOEL	President and CEO	Nov 17 '25	Sale	6.04	15,680	94,643	832,592	Nov 19 04:01 PM
LEWIS JOEL	President and CEO	Nov 18 '25	Sale	6.15	6,783	41,723	832,592	Nov 19 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 18 '25	Option Exercise	1.64	46,310	75,851	35,714	Nov 19 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 17 '25	Option Exercise	1.38	31,610	43,706	27,315	Nov 19 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 18 '25	Sale	6.22	46,310	288,187	7,614	Nov 19 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 17 '25	Sale	6.03	31,610	190,662	7,614	Nov 19 04:01 PM
Jamil Khurram	Chief Medical Officer	Nov 13 '25	Option Exercise	2.17	99,250	215,038	45,979	Nov 14 04:02 PM
Jamil Khurram	Chief Medical Officer	Nov 13 '25	Sale	5.47	121,117	662,510	4,479	Nov 14 04:02 PM
Jamil Khurram	Officer	Nov 13 '25	Proposed Sale	5.45	121,117	660,088		Nov 13 05:03 PM
10X Fund, L.P.	10% Owner	Nov 11 '25	Sale	5.25	40,000	210,000	5,832,207	Nov 12 04:33 PM
LEWIS JOEL	President and CEO	Nov 10 '25	Option Exercise	2.39	1,867	4,462	834,459	Nov 12 04:01 PM
LEWIS JOEL	President and CEO	Nov 10 '25	Sale	6.03	1,867	11,252	832,592	Nov 12 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 10 '25	Option Exercise	1.46	5,291	7,717	9,694	Nov 12 04:01 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 10 '25	Sale	6.03	5,291	31,884	7,614	Nov 12 04:01 PM
LEWIS JOEL	President and CEO	Nov 05 '25	Option Exercise	2.39	200	478	832,792	Nov 07 04:09 PM
LEWIS JOEL	President and CEO	Nov 05 '25	Sale	6.00	200	1,200	832,592	Nov 07 04:09 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 05 '25	Option Exercise	1.60	600	962	7,814	Nov 07 04:07 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 05 '25	Sale	6.00	600	3,600	7,614	Nov 07 04:07 PM
LEWIS JOEL	President and CEO	Nov 04 '25	Option Exercise	2.39	14,420	34,464	847,012	Nov 05 04:06 PM
LEWIS JOEL	President and CEO	Nov 03 '25	Option Exercise	2.39	1,300	3,107	833,892	Nov 05 04:06 PM
LEWIS JOEL	President and CEO	Nov 04 '25	Sale	6.07	14,420	87,529	832,592	Nov 05 04:06 PM
LEWIS JOEL	President and CEO	Nov 03 '25	Sale	6.01	1,300	7,813	832,592	Nov 05 04:06 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 04 '25	Option Exercise	1.61	28,629	46,085	18,355	Nov 05 04:06 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 03 '25	Option Exercise	1.61	3,810	6,123	8,914	Nov 05 04:06 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 04 '25	Sale	6.07	28,629	173,778	7,614	Nov 05 04:06 PM
CALLICUTT JACK W	Chief Financial Officer	Nov 03 '25	Sale	6.01	3,810	22,898	7,614	Nov 05 04:06 PM

Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.

Chief Medical OfficerDr. Khurram Jamil M.D.

General CounselMr. Robert Tritt J.D.

Head of CMC & Pharmaceutical DevelopmentMr. Jim Wilkins Ph.D.

Executive Assistant & Officer ManagerMs. Beth Knowles

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GALT

Galectin Therapeutics Inc

Upgrade your Finviz experience